Novartis to manufacture CureVac’s Covid-19 vaccine candidate CVnCoV
Novartis has reached a preliminary agreement with CureVac to manufacture the mRNA and bulk drug product for the latter’s Covid-19 vaccine candidate CVnCoV. The companies are currently under